Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

Zacks Investment Research • 10 hours ago

ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.

Zacks Investment Research • Jun 18, 2026

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-.

Business Wire • Jun 17, 2026

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Seeking Alpha • Jun 10, 2026

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in.

Business Wire • May 28, 2026

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026. The Company's presentation will begin at 9:20 a.m. (ET). A live webcast of the event w.

Business Wire • May 27, 2026

Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • May 22, 2026

Reasons to Add AngioDynamics Stock to Your Portfolio for Now

ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.

Zacks Investment Research • May 19, 2026

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The data will be discus.

Business Wire • May 13, 2026

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • May 6, 2026